JPWO2022109010A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022109010A5 JPWO2022109010A5 JP2023528641A JP2023528641A JPWO2022109010A5 JP WO2022109010 A5 JPWO2022109010 A5 JP WO2022109010A5 JP 2023528641 A JP2023528641 A JP 2023528641A JP 2023528641 A JP2023528641 A JP 2023528641A JP WO2022109010 A5 JPWO2022109010 A5 JP WO2022109010A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 44
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 43
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 43
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 43
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 42
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100035139 Folate receptor alpha Human genes 0.000 claims 2
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115436P | 2020-11-18 | 2020-11-18 | |
| US63/115,436 | 2020-11-18 | ||
| PCT/US2021/059701 WO2022109010A1 (en) | 2020-11-18 | 2021-11-17 | Heavy chain antibodies binding to folate receptor alpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549851A JP2023549851A (ja) | 2023-11-29 |
| JP2023549851A5 JP2023549851A5 (https=) | 2024-11-25 |
| JPWO2022109010A5 true JPWO2022109010A5 (https=) | 2024-11-25 |
Family
ID=79024440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528641A Pending JP2023549851A (ja) | 2020-11-18 | 2021-11-17 | 葉酸受容体アルファに結合する重鎖抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240002498A1 (https=) |
| EP (1) | EP4247498A1 (https=) |
| JP (1) | JP2023549851A (https=) |
| KR (1) | KR20230110303A (https=) |
| CN (1) | CN116615253A (https=) |
| AR (1) | AR124084A1 (https=) |
| AU (1) | AU2021383743A1 (https=) |
| CA (1) | CA3199785A1 (https=) |
| CL (2) | CL2023001432A1 (https=) |
| CO (1) | CO2023006790A2 (https=) |
| CR (1) | CR20230259A (https=) |
| IL (1) | IL302670A (https=) |
| JO (1) | JOP20230109A1 (https=) |
| MX (1) | MX2023005693A (https=) |
| PE (1) | PE20231203A1 (https=) |
| TW (1) | TW202233684A (https=) |
| UY (1) | UY39522A (https=) |
| WO (1) | WO2022109010A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2025252094A1 (zh) * | 2024-06-05 | 2025-12-11 | 长春金赛药业有限责任公司 | 靶向叶酸受体α(FRα)的抗体、双特异性抗体和偶联物，及其制备和用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| DK3221355T3 (da) * | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| CN115925952A (zh) * | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| JP7776987B2 (ja) * | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
-
2021
- 2021-11-11 TW TW110142033A patent/TW202233684A/zh unknown
- 2021-11-17 EP EP21824720.3A patent/EP4247498A1/en active Pending
- 2021-11-17 CA CA3199785A patent/CA3199785A1/en active Pending
- 2021-11-17 MX MX2023005693A patent/MX2023005693A/es unknown
- 2021-11-17 KR KR1020237020120A patent/KR20230110303A/ko active Pending
- 2021-11-17 PE PE2023001680A patent/PE20231203A1/es unknown
- 2021-11-17 US US18/253,197 patent/US20240002498A1/en active Pending
- 2021-11-17 CR CR20230259A patent/CR20230259A/es unknown
- 2021-11-17 CN CN202180077625.6A patent/CN116615253A/zh active Pending
- 2021-11-17 AR ARP210103178A patent/AR124084A1/es unknown
- 2021-11-17 JP JP2023528641A patent/JP2023549851A/ja active Pending
- 2021-11-17 IL IL302670A patent/IL302670A/en unknown
- 2021-11-17 AU AU2021383743A patent/AU2021383743A1/en active Pending
- 2021-11-17 WO PCT/US2021/059701 patent/WO2022109010A1/en not_active Ceased
- 2021-11-18 UY UY0001039522A patent/UY39522A/es unknown
-
2023
- 2023-05-18 JO JOJO/P/2023/0109A patent/JOP20230109A1/ar unknown
- 2023-05-18 CL CL2023001432A patent/CL2023001432A1/es unknown
- 2023-05-25 CO CONC2023/0006790A patent/CO2023006790A2/es unknown
-
2025
- 2025-10-14 CL CL2025003126A patent/CL2025003126A1/es unknown